Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	80	250.01	40.91	37.42	171.13
Revenue Growth (YoY)	-68.00%	511.16%	9.33%	-78.14%	63.93%
Cost of Revenue	127.37	92.17	55.76	73.79	108.75
Gross Profit	-47.37	157.84	-14.86	-36.37	62.38
Selling, General & Admin	35.92	35.82	30.98	37.25	34.99
Operating Expenses	35.92	35.82	30.98	37.25	34.99
Operating Income	-83.29	122.01	-45.84	-73.62	27.38
Interest Expense	-	-	-	-0.39	-
Interest & Investment Income	18.95	11.72	4.45	-	1.66
EBT Excluding Unusual Items	-64.34	133.74	-41.39	-74.01	29.04
Gain (Loss) on Sale of Investments	-	-	-	2.81	7.7
Other Unusual Items	-	-	-5	-	-
Pretax Income	-64.34	133.74	-46.39	-71.2	36.74
Income Tax Expense	0.67	1.41	0.02	-	-
Net Income	-65	132.33	-46.41	-71.2	36.74
Net Income to Common	-65	132.33	-46.41	-71.2	36.74
Shares Outstanding (Basic)	58	43	38	38	37
Shares Outstanding (Diluted)	58	45	38	38	37
Shares Change (YoY)	29.39%	16.20%	1.83%	0.86%	4.04%
EPS (Basic)	-1.13	3.08	-1.21	-1.89	0.99
EPS (Diluted)	-1.13	2.97	-1.21	-1.89	0.98
Free Cash Flow	-18.83	74.66	-15	-55.13	-108.81
Free Cash Flow Per Share	-0.33	1.68	-0.39	-1.46	-2.91
Gross Margin	-59.21%	63.13%	-36.32%	-97.21%	36.45%
Operating Margin	-104.11%	48.80%	-112.05%	-196.76%	16.00%
Profit Margin	-81.25%	52.93%	-113.45%	-190.29%	21.47%
Free Cash Flow Margin	-23.54%	29.86%	-36.67%	-147.36%	-63.59%
EBITDA	-78.56	126.46	-39.65	-68.45	31.2
EBITDA Margin	-98.19%	50.58%	-96.92%	-182.96%	18.23%
D&A For EBITDA	4.73	4.44	6.19	5.17	3.82
EBIT	-83.29	122.01	-45.84	-73.62	27.38
EBIT Margin	-104.11%	48.80%	-112.05%	-196.76%	16.00%
Effective Tax Rate	-	1.05%	-	-	-

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q